Results 21 to 30 of about 591,781 (298)

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure

Translational Oncology, 2018
OBJECTIVE: Asian melanoma patients, predominantly comprised of acral and mucosal subtypes, might not benefit from immunotherapy and targeted therapy as much as Caucasian patients.
ChuanLiang Cui, Li Zhou, Bin Lian, Lu Si, XiNan Sheng, ZhiHong Chi, Yan Kong, Xuan Wang, BiXia Tang, LiLi Mao, SiMing Li, Jie Dai, XieQiao Yan, Xue Bai, Jun Guo   +14 more
doaj   +1 more source

Efficacy and Safety of Paclitaxel, Ifosfamide and Cisplatin as First-line Treatment on Patients with Intermediate- or Poor-risk Advanced Testicular Cancer

Zhongliu Fangzhi Yanjiu, 2018
Objective To assess the efficacy and safety of paclitaxel, ifosfamide and cisplatin (TIP) as the first-line treatment for the patients with intermediate- or poor-risk testicular cancer retrospectively.
ZHOU Li, CHI Zhihong, CUI Chuanliang, SHENG Xi'nan, SI Lu, TANG Bixia, MAO Lili, WANG Xuan, YAN Xieqiao, LIAN Bin, LI Siming, BAI Xue, GUO Jun   +12 more
doaj   +1 more source

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study

BMC Cancer, 2023
Background Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands PD-L1 and PD-L2.
Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, Jianfu Zhao, Qing Xu, Renbing Jiang, Xuan Wang, Taiyang Ma, Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, Yiwei Dou, Qian Tan, Di Wu, Jun Guo   +19 more
doaj   +1 more source

Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure [PDF]

, 2002
Background: The cytotoxic treatment of patients suffering from advanced or metastatic cancer undergoing hemodialysis due to chronic renal failure still remains a problem, since for those patients pharmacokinetic and pharmacodynamic data on most cytotoxic
Stemmler, J., Hacker, U., Schalhorn, A., Weise, A., Heinemann, Volker   +4 more
core   +1 more source

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

Journal of Hematology & Oncology, 2018
Background Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T cell therapy in the treatment of other solid tumors has been limited.
Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Zhihong Chi, Xinan Sheng, Lu Si, Chuanliang Cui, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong, Jun Guo   +13 more
doaj   +1 more source

Significance of chromosome 9p status in renal cell carcinoma:a systematic review and quality of the reported studies [PDF]

, 2014
Defining the prognosis of renal cell carcinoma (RCC) using genetic tests is an evolving area. The prognostic significance of 9p status in RCC, although described in the literature, remains underutilised in clinical practice. The study explored the causes
El-Mokadem, Ismail, Fitzpatrick, John, Cunningham, J., Nabi, Ghulam, Pratt, Norman, Fleming, Stewart, Rai, Bhavan   +6 more
core   +1 more source

Temsirolimus for patients with metastatic renal cell carcinoma : outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center [PDF]

, 2014
Aim: Temsirolimus has shown efficacy as first-line treatment of patients with metastatic renal cell carcinoma and poor prognostic features. The efficacy of temsirolimus in other clinical settings, such as second-line therapy, is unclear.
Pascoe, Jennifer, Afshar, Mehran, Porfiri, Emilio, Whitmarsh, Sue, James, Nicholas D.   +4 more
core   +1 more source

UBE2QL1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene [PDF]

, 2013
Investigation of rare familial forms of renal cell carcinoma (RCC) has led to the identification of genes such as VHL and MET that are also implicated in the pathogenesis of sporadic RCC. In order to identify a novel candidate renal tumor suppressor gene,
Hodgson, S, Morris, Mark R., Turnell, Andrew S., Woodward, ER, Prigmore, Elena, Woodward, Emma R.; id_orcid, Wake, NC, Wake, Naomi C., Gribble, Susan M., Ricketts, Christopher J., Skytte, AB, Brown, Michael, Banks, RE, Morris, MR, Prigmore, E, Maher, ER, Woodward, Emma R., Clarke, Noel, Hodgson, Shirley, Skytte, Anne-bine, Ricketts, CJ, Turnell, AS, Brown, Michael; id_orcid, Maher, Eamonn R., Clarke, N, Banks, Rosamonde E., Gribble, SM, Brown, M, Skytte, Anne Bine   +28 more
core   +1 more source

Succinate dehydrogenase (SDH)-deficient renal carcinoma:a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients [PDF]

, 2014
Succinate dehydrogenase (SDH)-deficient renal carcinoma has been accepted as a provisional entity in the 2013 International Society of Urological Pathology Vancouver Classification.
Sedivcová, Monika, Yu, Darryl, Papathomas, Thomas, Niemeijer, Nicolasine D., Przybycin, Christopher, Nicoll, Katherine D, Paik, Julie, Miettinen, Markku, Yong, Jim L., Kedziora, Andrew, Andresen, Per Arne, Hes, Ondrej, Toon, Christopher W., Robinson, Bruce G, Corssmit, Eleonora P M, Michal, Michal, Chou, Angela, Hills, Kirsten, Nicoll, Katherine D., Clarkson, Adele, Clifton-bligh, Roderick J., Yong, Jim L, Maclean, Fiona, Yilmaz, Asli, Vlatkovic, Ljiljana, Niemeijer, Nicolasine D, Hartmann, Arndt, Sibony, Mathilde, Agaimy, Abbas, McKenney, Jesse K, Robinson, Bruce G., Van Leenders, Geert J.l.h., Chow, Chung W., Sioson, Loretta, Mckenney, Jesse K., Corssmit, Eleonora P.m., Tan, Puay Hoon, van Leenders, Geert J L H, Yakirevich, Evgeny, Trpkov, Kiril, Benn, Diana E., Gill, Anthony J., Chow, Chung W, Watson, Nicole, Fleming, Stewart, Magi-Galluzzi, Cristina, Clifton-Bligh, Roderick J   +46 more
core   +1 more source

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Journal of Hematology & Oncology, 2019
Background JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies.
Bixia Tang, Xieqiao Yan, Xinan Sheng, Lu Si, Chuanliang Cui, Yan Kong, Lili Mao, Bin Lian, Xue Bai, Xuan Wang, Siming Li, Li Zhou, Jiayi Yu, Jie Dai, Kai Wang, Jinwei Hu, Lihou Dong, Haifeng Song, Hai Wu, Hui Feng, Sheng Yao, Zhihong Chi, Jun Guo   +22 more
doaj   +1 more source